Condition
Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma
Total Trials
3
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (1)
P 2 (1)
Trial Status
Completed1
Recruiting1
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT03093909Phase 1Recruiting
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
NCT03004586Not ApplicableCompletedPrimary
Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Using a 22 vs 25-Gauge Needle
NCT03004105Phase 2WithdrawnPrimary
MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
Showing all 3 trials